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The SIRT1 deacetylase inhibits fat synthesis and stimulates
fat oxidation in response to fasting, but the underlying mecha-
nisms remain unclear. Here we report that SREBP-1c, a key
lipogenic activator, is an in vivo target of SIRT1. SIRT1 inter-
action with SREBP-1c was increased during fasting and
decreasedupon feeding, and consistently, SREBP-1c acetylation
levels were decreased during fasting in mouse liver. Acetylated
SREBP-1c levels were also increased inHepG2 cells treatedwith
insulin and glucose tomimic feeding conditions, and down-reg-
ulation of p300 by siRNA decreased the acetylation. Depletion
of hepatic SIRT1 by adenoviral siRNA increased acetylation of
SREBP-1c with increased lipogenic gene expression. Tandem
mass spectrometry and mutagenesis studies revealed that
SREBP-1c is acetylated by p300 at Lys-289 and Lys-309. Mech-
anistic studies using acetylation-defective mutants showed that
SIRT1 deacetylates and inhibits SREBP-1c transactivation by
decreasing its stability and its occupancy at the lipogenic genes.
Remarkably, SREBP-1c acetylation levels were elevated in diet-
induced obese mice, and hepatic overexpression of SIRT1 or
treatment with resveratrol, a SIRT1 activator, daily for 1 week
decreased acetylated SREBP-1c levels with beneficial functional
outcomes. These results demonstrate an intriguing connection
between elevated SREBP-1c acetylation and increased lipogenic
gene expression, suggesting that abnormally elevated SREBP-1c
acetylation increases SREBP-1c lipogenic activity in obesemice.
Reducing acetylation of SREBP-1c by targeting SIRT1 may be
useful for treating metabolic disorders, including fatty liver,
obesity, and type II diabetes.
The NAD-dependent SIRT1 (sirtuin 1) deacetylase plays a
critical role in cellular metabolism, stress responses, and possi-
bly aging bymodulating the activity of transcription factors and
cofactors by protein deacetylation (1–4). In response to low
nutritional availability, SIRT1 functions as a master switch to
maintain lipid and glucose homeostasis and energy balance by
regulating important metabolic regulators, such as PGC-1
(PPAR coactivator ), Foxo-1, and liver X receptor (1, 5–7).
We recently identified the nuclear bile acid receptor, farnesoid
X receptor (FXR),3 as an important in vivo target of SIRT1 in the
regulation of hepatic lipid metabolism (8). Of these reported
regulators, the function of SIRT1 in deacetylating and enhanc-
ing the activity of PGC-1 has beenwell established (1, 5, 9, 10).
SIRT1 deacetylation of PGC-1 increases its activity, which
enhances the expression of metabolic genes involved in
hepatic gluconeogenesis, fatty acid -oxidation, and mito-
chondrial function (1, 3, 11). It was recently demonstrated
that acute down-regulation of SIRT1 in mouse liver using
adenoviral delivery increased expression of lipogenic genes and
decreased expression of genes involved in fatty acid-oxidation
and bile acid biosynthesis (5). Consistent with these observa-
tions, activation of SIRT1 by treatment with SIRT1 activators,
such as a natural pleiotropic activator, resveratrol, or a syn-
thetic activator, SIRT1720, improved mitochondrial function,
increased fat oxidation, and decreased fat synthesis by increas-
ing deacetylation of PGC-1 (12–14).
Sterol response element-binding proteins belong to the basic
helix-loop-helix leucine zipper family of DNA binding tran-
scription factors (15–17). SREBP-1a and -1c (sterol response
element-binding protein 1a and 1c, respectively) are produced
from the same gene, and SREBP-2 is encoded by a separate gene
(15, 18). SREBP-1c contains 4 unique amino acids in its N ter-
minus but lacks 28 acidic amino acids that are present in
SREBP-1a (15, 19, 20). Expression of SREBP-1c is more abun-
dant than expression of SREBP-1a in adult liver, whereas
SREBP-1a is the predominant isoform in HepG2 cells (15–17).
SREBP-2 plays a crucial role in the regulation of cholesterol
synthesis, and SREBP-1a and -1c control expression of fatty
acid and triglyceride synthesis (18). In response to feeding,
SREBP-1c binds to its lipogenic target genes, such as fatty acid
synthase (Fas), and to its own gene and thereby stimulates
hepatic lipogenesis (15, 21–23). We and others showed that
SREBP-1c also plays a role in suppression of hepatic bile acid
* Thisworkwas supported, inwholeor inpart, byNational Institutes ofHealth
Grants CA103867 and CA124760 (to C.-M. C.), DK062777, and DK80032 (to
J. K. K.) and National Institutes of Health, NCI, Contract N01-CO-12400 (to
T. D. V.). This work was also supported by an American Diabetes Associa-
tion basic research award (to J. K. K.).
□S The on-line version of this article (available at http://www.jbc.org) contains
supplemental Figs. S1–S7.
1 Both authors contributed equally to this work.
2 To whom correspondence should be addressed: 407 S. Goodwin Ave.,
Urbana, IL61801. Tel.: 217-333-6317; Fax: 217-333-1133; E-mail: jongsook@
uiuc.edu.
3 The abbreviations used are: FXR, farnesoid X receptor; Nam, nicotinamide;
CHX, cycloheximide; IP, immunoprecipitation; Ad, adenovirus.
THE JOURNAL OF BIOLOGICAL CHEMISTRY VOL. 285, NO. 44, pp. 33959–33970, October 29, 2010
Printed in the U.S.A.
OCTOBER 29, 2010•VOLUME 285•NUMBER 44 JOURNAL OF BIOLOGICAL CHEMISTRY 33959
 by guest on January 8, 2020
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
biosynthesis in response to insulin under feeding conditions by
inhibiting transcription of Cyp7a1 (cholesterol 7 hydroxyl-
ase), the rate-limiting bile acid synthetic enzyme (24, 25).
The activity of SREBP-1 was shown to be regulated by post-
translational modifications, such as phosphorylation, ubiquiti-
nation, and acetylation (26–29). A ubiquitin ligase, Fbw7, was
shown to interact with SREBP-1 and enhances its ubiquitina-
tion in a phosphorylation-dependent manner (28). Further, a
functional interplay between ubiquitination and acetylation of
SREBP-1a was also reported (27). It was also demonstrated that
GSK3 or a salt-inducible kinase negatively regulates lipogenic
activity of SREBP-1c by phosphorylation (29, 30).
Although extensive studies have shown beneficial functions
of SIRT1 in metabolic regulation, how SIRT1 inhibits hepatic
lipogenesis and whether a key lipogenic activator SREBP-1c is
an in vivo target of SIRT1 is not fully understood. Using in vivo
animal studies as well as molecular and cellular studies, we
obtained compelling evidence indicating that SREBP-1c is an
important in vivo target of SIRT1 in the regulation of hepatic
lipid metabolism. Lys-289 and Lys-309 near and within the
DNA binding domain of SREBP-1c, respectively, is the target
of p300 acetylase and SIRT1 deacetylase. Deacetylation of
SREBP-1c by SIRT1 inhibited SREBP-1c activity by decreasing
its stability and its association with its lipogenic target gene
promoters. SREBP-1c acetylation levels were dynamically
regulated during fasting and feeding cycles and increased in
HepG2 cells treated with insulin and glucose. Remarkably,
SREBP-1c acetylation levels were highly elevated in diet-in-
duced obese mice, and overexpression of SIRT1 decreased the
acetylation levels with changes in metabolic gene expression
expected to be beneficial.
EXPERIMENTAL PROCEDURES
Cell Culture and Transfection Assay—COS-1 cells and
mouse hepatoma cells (Hepa1c1c7) were maintained in Dul-
becco’s modified Eagle’s medium (DMEM) at 37 °C and 5%
CO2. Human hepatoma HepG2 cells (ATCC HB8065) were
maintained in DMEM/F-12 (1:1) medium. Media were sup-
plemented with 10% fetal bovine serum and 100 units/ml pen-
icillin/streptomycin. Cell-based functional reporter assays
were performed as described previously (24, 31). COS-1 or
Hepa1c1c7 cells were transfected using Lipofectamine, and
HepG2 cells were transfected by electroporation to improve
transfection efficiency. SREBP-1cmutants were constructed by
site-directed mutagenesis (Stratagene, Inc.) and confirmed by
sequencing.
Animal Experiments and Tail Vein Injection of Adenoviral
Vectors—8–10-week-old male BALB/c mice were maintained
on a 12-h light and 12-h dark cycle. Mice were randomly
divided into groups and fasted overnight with free access to
water or fasted overnight and then fed standard chow for 3 h
as described previously (8, 24). Normal or obese mice were
injected with Ad-FLAG-SIRT1, Ad-siSIRT1, or control Ad-
empty (0.5–1.0 109 active viral particles in 200l of PBS), and
5–7 days after infection, mice were fasted overnight, and livers
were collected for further analysis. For the diet-induced obese
mouse studies, 8-week-old BALB/c mice were fed with either a
standard normal chow or a high fat diet (42% from fat; Harland
Teklad TD88137) for 16–20 weeks. Diet-induced obese mice
were infected with Ad-FLAG-SIRT1, and 1 week later, livers
were collected for acetylation assays. All of the animal use and
adenoviral protocols were approved by the Institutional Use
and Care of Animals and Biosafety Committees at the Univer-
sity of Illinois and were in accordance with National Institutes
of Health guidelines.
Cycloheximide (CHX) Experiments—CHX experiments were
performed as described previously (32). COS-1 cells were co-
transfected with plasmids for SREBP-1c wild type or mutants,
along with CMV-His6-p300 (33) or CMV-HA-SIRT1 (34), and
then treatedwithCHX (10g/ml) for the times indicated in the
figure legends. Cell extracts were prepared, and SREBP-1c lev-
els were detected by Western analysis.
In-cell Ubiquitination Assays—Because of poor transfec-
tion efficiency in HepG2 cells, in-cell ubiquitination studies
utilizing transfection were carried out in mouse Hepa1c1c7
cells. Cells were transfected with expression plasmids for
SREBP-1c and HA-ubiquitin in the presence of SIRT1
expression plasmid. Cells were treated with 5 M MG132 for
5 h, and cell extracts were prepared under denaturing condi-
tions using radioimmune precipitation buffer (50mMTris-HCl,
pH 7.5, 1 mM EDTA, 1% Nonidet P-40, 1% sodium deoxy-
cholate, 0.1% SDS). FLAG-SREBP-1c was immunoprecipitated
with M2 antibody (Sigma), and after washing in radioimmune
precipitation buffer, proteins were separated by SDS-PAGE,
andHA-ubiquitinated FLAG-SREBP-1c was detected byWest-
ern analyses using HA or ubiquitin antibody.
In Vitro, In-cell, and in Vivo Acetylation and Deacetylation
Assays—For in-cell assays, COS-1 or mouse Hepa1c1c7 cells in
6-well plates were cotransfected with expression plasmids for
FLAG-SREBP-1c, p300, and/or SIRT1. For adenoviral experi-
ments, HepG2 cells were infected with an adenoviral vector
expressing p300 siRNA (35) or a control vector, and 24 h later,
cells were incubated in serum-free low glucose (5 mM)medium
overnight and then treated with insulin (100 nM) and high glu-
cose (25 mM) for 30 min. To inhibit deacetylase activity, cells
were treated with deacetylase inhibitors, 500 nM trichostatin A,
and freshly prepared 10 mM nicotinamide (Nam) for 2–5 h
before preparing the cell extracts.
For in vivo acetylation assays, liver nuclear extracts were pre-
pared in the presence of deacetylase inhibitors. Endogenous
SREBP-1c was immunoprecipitated at 4 °C for 2 h in radioim-
mune precipitation buffer andwashed four times with radioim-
mune precipitation buffer. Acetylated SREBP-1c levels were
detected by Western analyses using acetyl-Lys antibody (Cell
Signaling, Inc.).
For in vitro deacetylation assays, COS-1 cells (four 150-mm
plates) were transfectedwith FLAG-SREBP-1c expression plas-
mids, and 48 h later, FLAG-SREBP-1c was isolated by M2 aga-
rose and incubated with purified p300 and acetyl-CoA in buffer
(50 mMHepes, pH. 7.9, 10% glycerol). After incubation at 30 °C
for 30 min, the beads were thoroughly washed, and acetylated
FLAG-SREBP-1c was incubated with purified GST or GST-
SIRT1 in the presence of 50 M NAD in deacetylation buffer
(Tris-HCl, pH 8.8, 5% glycerol, 50mMNaCl, 4mMMgCl2, 1mM
DTT) at 37 °C for 1 h. Proteins were separated by SDS-PAGE,
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and acetylated SREBP-1c was detected by Western analysis
using acetyl-Lys antibody.
Quantitative RT-PCR—Total RNAwas isolated using TRIzol
reagent (Invitrogen). Real-time RT-PCR was performed with
an iCycler iQ (Bio-Rad) using SYBR Green PCR master mix.
Target gene mRNA levels were normalized to those of 36B4.
Co-IP and Chromatin IP (ChIP) Assays—Co-IP and ChIP
assays were performed as described (8, 24, 32, 36, 37). For ChIP
assays, HepG2 cells were transfected with expression plasmids
using electroporation, and cells were incubated with serum-
free low glucose medium overnight and then treated with 100
nM insulin and 25 mM glucose for 30 min and used for ChIP
assays. Sequences of the primers for quantitative RT-PCR and
ChIP assays are available upon request.
RESULTS
SIRT1 Directly Interacts with and Deacetylates SREBP-1c—
To examine whether SIRT1 directly interacts with SREBP-1c,
in vitro GST pull-down assays were performed. SREBP-1c
interacted with full-length SIRT1 and a fragment (amino acids
214–441) containing the catalytic
domain (Fig. 1, A and B). Because
SIRT1 directly interacts with SREBP-
1c through the catalytic domain,
we asked whether SIRT1 can
deacetylate SREBP-1c using in vitro
deacetylation assays. SREBP-1c pro-
teins were expressed in cells, puri-
fied, and used in deacetylation
assays (Fig. 1C). Western analyses
showed that SREBP-1c is acetylated
in samples incubated with p300
(Fig. 1D, lanes 1 and 2). Incubation
of the acetylated SREBP-1c with
GST-SIRT1 resulted in an NAD-
dependent decrease in acetylation,
whereas no decrease was observed
with the control GST (Fig. 1D, lanes
3–5). These results indicate that
SIRT1 deacetylates SREBP-1c in vitro
in an NAD-dependent manner.
Deacetylation of SREBP-1c by
SIRT1 was further confirmed in
cells. SREBP-1c was immunopre-
cipitated under stringent conditions
with buffers containing SDS, and
acetylated SREBP-1c levels were
detected by Western analysis using
acetyl-Lys antibody. Co-expression
of SIRT1 wild type with p300 sub-
stantially reduced acetylation levels
of SREBP-1c by over 60% (Fig. 1, E
(lanes 2–4) and F), whereas co-ex-
pression of a SIRT1 mutant lacking
the deacetylase activity resulted in
increased acetylated SREBP-1c lev-
els (Fig. 1,E (lanes 2, 5, and 6) andF).
Similar results were observed with
SREBP-1 in mouse Hepa1c1c7 cells (Fig. 1G). These results
indicate that SIRT1 can deacetylate SREBP-1c in vitro and in
cells.
SIRT1 Deacetylates Hepatic SREBP-1c in Vivo—To directly
demonstrate that SIRT1 deacetylates SREBP-1c in vivo, endog-
enous SIRT1 in mouse liver was acutely down-regulated by tail
vein injection of an adenoviral vector expressing siRNA for
SIRT1 (Ad-siSIRT1), and acetylation levels of SREBP-1c were
examined (Fig. 2A). Hepatic SIRT1 levels were efficiently
reduced in fasted mice infected with Ad-siSIRT1 compared
withmice injectedwithAd-empty, whereas control tubulin lev-
els were not changed (Fig. 2B). SIRT1 depletion substantially
increased acetylation levels of endogenous SREBP-1c in the liv-
ers of fastedmice (Fig. 2,C andD). Consistently, the addition of
Nam, but not trichostatin A, to mouse liver extracts during
immunoprecipitation increased acetylation levels of endoge-
nous SREBP-1c (supplemental Fig. S1). These results suggest
that SIRT1 deacetylates SREBP-1c in mouse liver in vivo.
We also examined the effects of SIRT1 depletion on
hepatic expression of metabolic genes. Consistent with ele-
FIGURE 1. SIRT1 directly interacts with and deacetylates SREBP-1c. A, a schematic diagram of full-length
SIRT1 and deletionmutants. B, purified GST or GST-SIRT1 fusion proteins that had been bound to glutathione-
Sepharose were incubated with 35S-labeled SREBP-1c, and after washing, bound proteins were eluted and
analyzed by SDS-PAGE followed by autoradiography. C, experimental outline of in vitro deacetylation assays.
D, FLAG-SREBP-1c, acetylated by p300, was further incubated with GST control or GST-SIRT1 in the absence or
presence of NAD, and acetylated FLAG-SREBP-1c and FLAG-SREBP-1c in input samples were detected by
Western analysis (bottom). E–G, COS-1 (E and F) orHepa1c1c7 cells (G)were co-transfectedwith FLAG-SREBP-1c
and p300 expression plasmids with SIRT1 plasmids as indicated, and 36 h later, in-cell acetylation assays were
performed. SREBP-1c was immunoprecipitated from cell extracts under stringent conditions using SDS-con-
taining buffers, and acetylated SREBP-1cwas detected byWestern analysis. Duplicates are shown. Band inten-
sities of acetylated SREBP-1c were quantified using the ImageJ program, and the values from control samples
were set to 1. Statistical significancewas determined using Student’s t test. *, p 0.05 (n 3). aa, amino acids;
Ab, antibody;WB, Western blot; IP, immunoprecipitation. Error bars, S.E.
Inhibition of Hepatic SREBP-1c Activity by SIRT1
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vated SREBP-1c acetylation levels resulting from down-reg-
ulation of hepatic SIRT1, which is expected to increase activ-
ity of SREBP-1c, the expression of Srebp-1c and Fas, key
lipogenic genes, were significantly increased in these mice
(Fig. 2E). Furthermore, down-regulation of SIRT1 signifi-
cantly decreased expression of Cyp7a1 and Cyp8b1, hepatic
enzymes involved in the bile acid biosynthetic pathway. The
SIRT1 depletion also reduced the expression of a mitochon-
drial oxidative phosphorylation gene, cytochrome c, although
the decrease was not statistically significant. Expression of
fatty acid oxidation genes, such as Eci (enoyl-CoA isomer-
ase) and Mcad, was also decreased significantly in the
SIRT1-depleted mice. In contrast, expression of Ppar/, an
important regulator in energy balance (38), was not changed
in these mice. These in vivo studies demonstrate that SIRT1
deacetylates SREBP-1c in the mouse liver, which correlates
with beneficially expected gene expression patterns of lipid
metabolic genes.
SREBP-1 Acetylation Is Increased
under Feeding Mimic Conditions in
a p300-dependent Manner—Be-
cause SIRT1 deacetylates SREBP-1c
(Figs. 1 and 2) and NAD-depen-
dent SIRT1 activity is increased
under nutritional deprivation (1),
acetylation levels of SREBP-1 would
be expected to be decreased during
fasting and increased upon feeding.
To test this idea, we first examined
whether acetylation levels of endog-
enous SREBP-1 in HepG2 cells are
increased by treatment with insulin
and glucose tomimic feeding condi-
tions. Treatment with insulin and
glucose slightly increased acetyla-
tion levels of endogenous SREBP-1
(Fig. 3A, lanes 1 and 3). Further
treatmentwithNam, a SIRT1 inhib-
itor,markedly increased the acetyla-
tion levels (lanes 3 and 4). These
results suggest that acetylation of
endogenous SREBP-1 in HepG2
cells is increased under conditions
that mimic feeding and SIRT1 de-
acetylates SREBP-1.
Itwas previously reported from in
vitro and cell culture studies that
SREBPs are acetylated by p300/CBP
acetylases (27). To test whether
increased acetylation of SREBP-1 by
insulin and glucose treatment is
dependent on p300, endogenous
p300 in HepG2 cells was down-reg-
ulated by siRNA, and acetylated
SREBP-1 levels were detected. The
p300 levels were decreased in cells
infected with Ad-sip300, whereas
control tubulin levels were not (Fig.
3B). The acetylated SREBP-1 levels were decreased in cells
infected with adenoviral siRNA for p300 in a dose-dependent
manner (Fig. 3C). These results demonstrate that p300 acety-
lates SREBP-1 in HepG2 cells under conditions mimicking
feeding.
SREBP-1c Acetylation Is Dynamically Regulated by Fasting
andFeeding inVivo—Wenext examinedwhether acetylation of
SREBP-1c is regulated in response to fasting and feeding. Mice
were fasted overnight or refed after overnight fasting, and livers
were collected for further analyses (Fig. 3D). Hepatic SREBP-1c
protein levels were substantially increased upon feeding (Fig.
3E, a), which is consistent with elevatedmRNA levels of the key
lipogenic Fas gene, a well known SREBP-1c target (Fig. 3F).
Co-IP studies revealed that SREBP-1c interaction with SIRT1
was increased during fasting, whereas interaction with HNF-4
was increased during feeding (Fig. 3E, b–d). Consistently,
acetylated SREBP-1c was barely detectable in fasted mice (Fig.
3G). Due to the dynamic nature of acetylation and deacetyla-
FIGURE 2.Down-regulation of SIRT1 increases acetylated SREBP-1c levels in vivo. A, the experimental
procedure is shown.Micewere injectedwith Ad-siSIRT1 or control Ad-empty via tail veins, and 7 days later,
mice were fasted overnight, and livers were collected for further analysis. B, Western blotting was per-
formed to detect hepatic SIRT1 protein levels. C, endogenous SREBP-1c was immunoprecipitated, and
acetylated SREBP-1c levels were detected by Western analysis. Duplicates are shown. D, band intensities
of acetylated and total SREBP-1 were determined using ImageJ software, and acetylated SREBP-1 levels
relative to total levels from the mice infected with Ad-empty were set to 1. Statistical significance was
determined by Student’s t test. *, p  0.05 (n  3). E, the mRNA levels of the indicated genes were
determined by real-time quantitative RT-PCR in the same livers used for in vivo acetylation assays. Statis-
tical significance was determined by Student’s t test. * and NS, p  0.05 and statistically not significant,
respectively (n  5). IP, immunoprecipitation. Error bars, S.E.
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tion of SREBP-1c, it was challenging to consistently detect ele-
vated acetylation of endogenous SREBP-1c under feeding con-
ditions. These results, taken togetherwith acetylation studies in
vitro, in cells, and in vivo (Figs. 1–3), suggest that SIRT1
decreases acetylated SREBP-1c levels during fasting.
SREBP-1c Is Acetylated at Lys289 and Lys309 by p300—To
better understand the functional roles of SREBP-1c acetylation,
we sought to identify acetylation site(s) in SREBP-1c. It was
reported that the SREBP-1a isoform is acetylated by p300 at
Lys-333 in SREBP-1a (equivalent to Lys-309 in SREBP-1c) (27).
Using tandem mass spectrometry and mutagenesis studies, we
further identified Lys-289 as well as Lys-309 as acetylation sites
(Fig. 4, A–D). Lys-289 and Lys-309 are highly conserved in
vertebrates (Fig. 4E). To confirm these results, in-cell and in
vitro acetylation assays were performed using SREBP-1c mu-
tants (Fig. 4, F–I). Acetylation of
SREBP-1c wild type was substan-
tially increased in the presence of
p300 in COS-1 cells (Fig. 4G, lanes 1
and 2). Acetylation of SREBP-1cwas
not markedly decreased with the
K289R mutant, was somewhat de-
creased with K309R mutant, and
wassubstantiallyreducedwithK289R/
K309R double mutant (Fig. 4,G and
H). To directly determine if both
residues are important for acetyla-
tion, in vitro acetylation assays were
performed. Acetylated SREBP-1c
was detectablewithwild type, K289R,
and K309R but was not detectable
with the K289R/K309R mutant (Fig.
4I). Comparable levels of SREBP-1c
wild type, K309R, and K289R/K309R
wereutilized in the invitroacetylation
assays (supplemental Fig. S2). These
results indicate that both Lys-289
and Lys-309 sites are important for
acetylation by p300.
SIRT1 Decreases the Stability of
SREBP-1c by Increasing Ubiqui-
tination—Acetylation of transcrip-
tional factors, such as p53, Foxo-1,
and FXR, influences their stability,
DNA binding, and protein-protein
interactions (6, 8, 27, 39). It was
reported that acetylation of SREBP-
1a increases its stability by preventing
its ubiquitination (27). To examine
whether SIRT1-mediated deacetyla-
tion alters SREBP-1c stability, we
first examined whether SIRT1 af-
fects ubiquitination of SREBP-1c.
Overexpression of a SIRT1 wild type
increased ubiquitinated SREBP-1c
levels (Fig. 5A, lanes 1–3). Further,
expression of a catalytically inactive
SIRT1 mutant decreased ubiquiti-
nated SREBP-1c levels and, consistently, increased acetylated
SREBP-1c levels (Fig. 5B, lanes 1–4). These results suggest that
SIRT1 increases ubiquitination of SREBP-1c, which should
decrease the stability of SREBP-1c.
To test the effects of p300 and SIRT1 on SREBP-1c stability,
we monitored protein degradation using CHX experiments.
SREBP-1cwas rapidly degradedwith a half-life of about 1 h (Fig.
5,C andD). Overexpression of p300 substantially increased the
half-life, and coexpression of SIRT1 wild type with p300 mark-
edly decreased the stability, reducing the half-life from about
6 h to about 1 h. In contrast, a smaller decrease was observed in
cells co-expressing a catalytically inactive SIRT1mutant. These
results indicate that p300 increases SREBP-1c stability and that
SIRT1 decreases SREBP-1c stability in a manner dependent on
it deacetylation activity.
FIGURE 3. SREBP-1 acetylation is increased under conditions that mimic feeding in a p300-dependent
manner. A, HepG2 cells were treated with vehicle or Nam (10mM) for 3 h and further treated with insulin (100
nM) and glucose (25 mM) for 30 min. Then cells were collected, and acetylation assays were carried out as
described in the legend to Fig. 1. Acetylated endogenous SREBP-1 levels were detected by Western analysis.
B and C, HepG2 cells were infected with Ad-sip300, and 48 h later, cells were treated with the HDAC inhibitors
trichostatinA andNam for 3h and further treatedwith insulin andglucose. Protein levels of p300, SREBP-1, and
acetylated endogenous SREBP-1 were detected. D, experimental outline. E (a), protein levels in input samples
were detected byWestern analysis. E (b, c, and d), co-IP protein interaction studies were done using antibodies
as indicated. F, the mRNA levels of FAS were measured by quantitative RT-PCR. Statistical significance was
determined using Student’s t test. *, p 0.05 (n 3). G, endogenous SREBP-1c was immunoprecipitated and
acetylated SREBP-1c levels were detected (left). Conversely, acetylated proteins were immunoprecipitated by
acetyl-Lys antibody, and then acetylated SREBP-1c proteins were detected using SREBP-1 antibody (right). IP,
immunoprecipitation;WB, Western blot. Error bars, S.E.
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We further analyzed the role of SREBP-1c acetylation in pro-
tein stability using the acetylation-defective mutants. Overex-
pression of p300 robustly increased the half-life of SREBP-1c
wild type, and additional expression
of SIRT1 substantially decreased it
(Fig. 5, E and I). In contrast, these
effects were not observed with the
K289R, K309R, and K289R/K309R
mutants (Fig. 5, F–I). These results
suggest that acetylation at Lys-289
and Lys-309 increases SREBP-1c
stability, and SIRT1 decreases its
stability.
SIRT1 Reduces SREBP-1c Occu-
pancy at Lipogenic Target Promo-
ters—Because acetylation of tran-
scription factors affected their
DNA binding ability (6, 8, 39) and
Lys-289 and Lys-309 are present
near and within the DBD of SREBP-
1c, respectively, we next sought to
determine the effects of SREBP-1c
acetylation on DNA binding. ChIP
assays were performed in HepG2
cells overexpressing p300. Although
occupancy of SREBP-1c and RNA
polymerase II at the Fas and Srebp-1c
promoters was increased in cells
expressing p300, the occupancy
was decreased in cells co-express-
ing SIRT1 (Fig. 6A and supplemen-
tal Fig. S3). These results indicate
that p300-mediated acetylation in-
creases, whereas SIRT1-mediated
deacetylation decreases, the SREBP-
1c occupancy at the promoters.
We also examined the effect of
SREBP-1c acetylation on the ex-
pression of these genes. The Fas
and Srebp-1c mRNA levels were
increased in HepG2 cells co-
expressing SREBP-1c with p300,
whereas additional expression of
SIRT1 significantly reversed the
increase (Fig. 6B). Consistently, cell-
based reporter assays showed that
down-regulation of SIRT1 using
siRNA increased SREBP-1c transac-
tivation of the Fas promoter (sup-
plemental Figs. S4 and S5).
Because SREBP-1c acetylation was increased in mice under
feeding conditions and in HepG2 cells by treatment with insulin
(Fig. 3), we next examined the effects of insulin treatment on
FIGURE 4. Lys-289 and Lys-309 are themajor sites in SREBP-1c acetylated by p300. A, the experimental protocol for MS/MS analysis is outlined. B, purified
GST or GST-SREBP-1c was incubated with p300, and proteins were separated using SDS-PAGE followed by Western analysis. C, MS/MS analysis of acetylated
SREBP-1c is shown, which identifies Lys-289 as a site acetylated by p300. D, a schematic diagram of the acetylation sites in SREBP-1c. E, alignments of the
SREBP-1c region containing Lys-289 or Lys-309 from different vertebrates. F, outline of experimental protocols. G, COS-1 cells were transfected with plasmids
as indicated, and acetylation assays were performed as described in the legend to Fig. 1. H, band intensities of acetylated SREBP-1c were quantified, and the
values from wild type samples were set to 1. Consistent results were observed from two additional assays. I, in vitro acetylation assays were performed as
described under “Experimental Procedures.” Acetylated FLAG-SREBP-1c was detected by Western analysis. IP, immunoprecipitation; WB, Western blot. Error
bars, S.E.
FIGURE 5. SIRT1 decreases SREBP-1c stability, which is correlatedwith increased ubiquitination.A and B,
Hepa1c1c7 cells were transfected with plasmids as indicated, and in-cell ubiquitination assays were per-
formed. FLAG-SREBP-1c was immunoprecipitated in SDS-containing buffers, and ubiquitinated FLAG-
SREBP-1c was detected byWestern analysis. Ubiquitinated FLAG-SREBP-1c is indicated by a dotted line. FLAG-
SREBP-1c levels in input are shown at the bottom. In B, acetylated SREBP-1c levels were detected by Western
analysis using acetyl-Lys antibody. C–I, CHX experiments. COS-1 cells were transfected with plasmids as indi-
cated, and 36 h later, cells were treated with CHX for the indicated times, and SREBP-1 levels were detected.
Membranes were stripped, and tubulin levels were detected. D and I, band intensities were measured and
normalized to the values from the zero timepoints, whichwere set to 1. Consistent resultswere observed from
two independent CHX assays. Ub, ubiquitin; IP, immunoprecipitation;WB, Western blot.
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SREBP-1c binding to the Fas gene promoter (Fig. 6C). The
SREBP-1coccupancy at theFaspromoterwasmarkedly increased
upon insulin treatment, and overexpression of SIRT1 decreased
SREBP-1c occupancy (Fig. 6D). In contrast, the occupancy of wild
type SREBP-1c at the control GAPDH coding region was not
detected (Fig. 6E). Association of RNA polymerase II was mark-
edlydecreased incellsoverexpressingSIRT1(Fig. 6D). In contrast,
occupancy of theK289Rmutantwas detected but not increased
by insulin treatment, and remarkably, occupancy of the K289R/
K309R double mutant was not detectable (Fig. 6D). Consis-
tently, occupancy of the SREBP-1c K289R/K309R double
mutant and RNA polymerase II was substantially decreased at
the Srebp-1c promoter (Fig. 6F and supplemental Figs. S6 and
S7). These results suggest that SIRT1 deacetylates and inhibits
SREBP-1c transactivation, at least in part, by inhibiting its
occupancy at target promoters.
SREBP-1c Acetylation Levels Are Highly Elevated in Diet-in-
duced Obese Mice—Hepatic SREBP-1c levels are highly ele-
vated in fatty livers of animal models of obesity and type II
diabetes (40). Because acetylation of SREBP-1c increases its
transactivation ability by increasing protein stability and pro-
moter occupancy at lipogenic target genes (Figs. 5 and 6), we
asked whether SREBP-1c acetylation levels are abnormally ele-
vated in a metabolic disease state model using diet-induced
obese (DIO) mice (Fig. 7A). As previously reported (12, 13, 40),
SIRT1 levels were substantially decreased, and SREBP-1c levels
were increased in livers of obese mice (Fig. 7B), confirming the
effectiveness of the chronic high fat diet. Consistent with
decreased SIRT1 levels in these mice, acetylated SREBP-1c lev-
els were dramatically increased compared with control mice
(Fig. 7, C and D). The mRNA levels of SREBP-1c target genes,
such as Srebp-1c itself and Fas, were significantly increased in
the diet-induced obese mice, and mRNA levels of bile acid bio-
synthetic genes, Cyp7a1 and Cyp8b1, were substantially
decreased (Fig. 7E). In obese mice, expression of cytochrome c
was significantly reduced, and genes involved in fatty acid
oxidation, such as Eci andMcad, were also decreased, whereas
Cpt (carnitine palmitoyltransferase) gene expression was not
FIGURE 6. SIRT1 decreases occupancy of SREBP-1c at the Fas and Srebp-1c gene promoters. A, HepG2 cells were transfected with plasmids, as indicated,
using electroporation, and association of SREBP-1c or RNA pol II at the Fas and Srebp-1c promoters was detected by ChIP assays. B, themRNA levels of Fas and
Srebp-1c genes were detected by quantitative RT-PCR in parallel. Statistical significance was determined by Student’s t test. *, p  0.05 (n  3). C, the
experimental procedure is outlined.D and E, HepG2cellswere transfectedwith SREBP-1cwild typeormutantplasmidsusingelectroporationas indicated. Cells
were treated with insulin (100 nM) for 30min and collected for ChIP assays to detect occupancy of SREBP-1c at the Fas promoter (D), Srebp-1c promoter (F), or
GAPDH coding region (E). Consistent results were observed from two independent assays. IP, immunoprecipitation. Error bars, S.E.
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changed. Expression of Ppar/ was also significantly de-
creased in obese mice. These patterns of gene expression are
similar to those observed in SIRT1-depleted mice (Fig. 2E) and
demonstrate that elevated SREBP-1c acetylation levels corre-
late with gene expression patterns expected to be deleterious.
Overexpression of Hepatic SIRT1 Decreases SREBP-1c Acety-
lation Levels in Obese Mice—Our in vivo acetylation studies in
mice infected with Ad-siSIRT1 (Fig. 2) and diet-induced obese
mice (Fig. 7) showed an intriguing correlation between elevated
SREBP-1c acetylation levels and detrimental lipid metabolic
gene expression profiles. To test whether overexpression of
SIRT1 could reverse these effects in the obese mice, Ad-FLAG-
SIRT1 was injected, andmice were fasted overnight, and acety-
lation of endogenous hepatic SREBP-1c was examined (Fig.
8A). Overexpression of SIRT1 (Fig. 8B) significantly decreased
SREBP-1c acetylation levels by 80% in the obese mice infected
with Ad-FLAG-SIRT1 (Fig. 8, C and D). Consistent with these
results, activation of SIRT1 by resveratrol, a SIRT1 activator
(12–14), substantially decreased hepatic acetylated SREBP-1c
levels (Fig. 8E). In quantitative RT-PCR analyses, mRNA levels
of Srebp-1c and Fas decreased inmice infected with Ad-FLAG-
SIRT1 (Fig. 8F). Overexpression of SIRT1 resulted in increased
expression of hepatic genes involved in fatty acid -oxidation
and mitochondrial function. These in vivo studies, taken
together with in vitro and cell studies, demonstrate that SIRT1
deacetylates and inhibits hepatic SREBP-1c activity by decreas-
ing its stability and promoter occupancy at the FAS and SREBP-
1c, which contributes to inhibition of hepatic lipogenesis.
DISCUSSION
Using adenovirus-mediated down-regulation or overexpres-
sion of SIRT1 in livers of normal and diet-induced obese mice,
as well as molecular, biochemical, and cellular studies, we have
obtained compelling evidence that the lipogenic activator
SREBP-1c is an important in vivo target of SIRT1.Tandemmass
spectrometry and mutagenesis studies revealed that Lys-289
and Lys-309 of SREBP-1c are targets of p300 acetylation
and SIRT1 deacetylation. SIRT1 deacetylates and inhibits
SREBP-1c activity by decreasing its stability and by decreasing
its occupancy at the lipogenic target gene promoters. Acetyla-
tion levels of endogenous SREBP-1c in liver were increased in
response to feeding and decreased by fasting, suggesting that
FIGURE 7. Acetylated SREBP-1c levels are highly elevated in diet-induced obese (DIO) mice. A, the experimental procedure. B, protein levels were
determined byWestern analysis. Results from twomice are shown. C, endogenous SREBP-1c was immunoprecipitated and acetylated SREBP-1c was detected
byWestern analysis.D, band intensities of acetylated and total SREBP-1 weremeasured, and acetylated SREBP-1 levels relative to total levels were calculated.
E, themRNA levels of the indicated geneswere determined by quantitative RT-PCR. Statistical significancewas determined by Student’s t test (n 4). *, **, and
NS, p 0.05, p 0.01, and statistically not significant, respectively. IP, immunoprecipitation;WB, Western blot. Error bars, S.E.
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SREBP-1c acetylation is normally dynamically regulated by
SIRT1. Consistently, depletion of endogenous SIRT1 by adeno-
viral siRNA substantially increased SREBP-1c acetylation lev-
els. Remarkably, hepatic SREBP-1c acetylation levels were
highly elevated in diet-induced obese mice, and adenovirus-
mediated overexpression of SIRT1 decreased SREBP-1c acety-
lation levels, resulting in changes in lipid metabolic gene ex-
pression patterns expected to be beneficial.
Our results are consistent with recent studies demonstrating
that SIRT1 plays a critical role in the regulation of hepatic lipid
metabolism (5, 41). Rodgers and Puigserver (5) originally re-
ported that acute down-regulation of endogenous SIRT1 in
mouse liver using adenoviral delivery increased expression of
lipogenic genes and decreased expression of genes involved in
fatty acid -oxidation and bile acid biosynthesis. Consistent
with these results, a recent knock-out mouse study demon-
strated that liver-specific deletion of SIRT1 decreased fatty acid
-oxidation by impairing PPAR/PGC-1 signaling, and these
mice developed hepatic steatosis and inflammation when chal-
lenged with a high fat diet (41). However, themolecular basis of
SIRT1 inhibition of fat synthetic gene expression and stimula-
tion of fat oxidative gene expression was not fully understood.
Our current studies suggest that SIRT1 contributes to such
beneficial lipid metabolic outcomes in the liver, at least in
part, by deacetylating SREBP-1c and inhibiting lipogenic
gene expression.
SREBP-1c is a key lipogenic activator and its expression is
dynamically regulated in response to nutritional and hormonal
FIGURE 8. Overexpression of SIRT1 in obese mice decreases SREBP-1c acetylation levels. A, outline of the experimental protocol. B, protein levels of
FLAG-SIRT1 were detected by Western blotting. C–E, endogenous SREBP-1c was immunoprecipitated from liver extracts from obese mice overexpressing
FLAG-SIRT1 (C) or mice treated orally with resveratrol daily for 1 week (E). Acetylated SREBP-1c levels were detected byWestern analysis.D, band intensities of
acetylated and total SREBP-1weremeasured, and acetylated SREBP-1 levels relative to total levels were calculated. F, themRNA levels of indicated geneswere
determined by quantitative RT-PCR. D and F, statistical significance was determined by Student’s t test, and S.E. was calculated (n 3). * and **, p 0.05 and
p 0.01, respectively. IP, immunoprecipitation;WB, Western blot. Error bars, S.E.
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cues (15–17, 23). SREBP-1c levels are transiently elevated upon
feeding and reduced by fasting in normal mice. In contrast,
SREBP-1c levels are constitutively and highly elevated in met-
abolic disease states, as detected in ob/ob mice and diet-in-
duced obese mice (40). Our studies show that SREBP-1c acety-
lation enhances SREBP-1c activity by increasing its stability and
recruitment to its lipogenic target promoters, which should
promote hepatic lipogenesis and further contribute to fatty
liver disease (hepatosteatosis), a condition associated with obe-
sity and insulin resistance. It was recently shown that SIRT1
levels were decreased in mice fed alcohol, and consistent with
the decreased SIRT1 levels, SREBP-1c acetylation levels were
elevated inmice fed ethanol (42). This report, together with our
current studies, suggests that SIRT1 is involved in the preven-
tion of non-alcoholic and alcoholic fatty liver by deacetylating
and suppressing SREBP-1c activity.
We observed that acetylation of SREBP-1c in liver is dynam-
ically increased upon feeding and decreased during fasting in
normal physiological conditions, but the levels were highly ele-
vated in diet-induced obese mice. Constitutively elevated
acetylation of SREBP-1c may underlie highly elevated hepatic
lipogenesis in these obese mice. In line with these results, we
also recently demonstrated that SIRT1 and p300 play impor-
tant roles in modulating activity of the nuclear bile acid recep-
tor FXR by dynamically acetylating and deacetylating FXR as
well as histones at the target gene promoter (8, 31). Remarkably,
in metabolic disease states, the interaction of SIRT1 with FXR
was substantially decreased, and hepatic FXR acetylation levels
were highly elevated (8). In these two studies, acetylation of
FXR or SREBP-1 increased protein stability by inhibiting ubiq-
uitination, but the opposite effects of acetylation on transacti-
vation of these two proteins were observed. Although acetyla-
tion of FXR resulted in inhibition of heterodimerization with
RXR and DNA binding, acetylation of SREBP-1c seemed to
increase the occupancy of SREBP-1c with its lipogenic target
gene promoters. These FXR and SREBP-1c studies suggest that
a dynamic balance between p300 and SIRT1 is important in
maintaining metabolic homeostasis, and disruption of this bal-
ance leads to hyperactivation or inactivation of metabolic reg-
ulators, such as SREBP-1c and FXR, respectively, resulting in
metabolic disorders. It will be important to understand how
p300 and SIRT1 activities are unbalanced in disease conditions
and which signaling pathways are involved.
We also observed that SREBP-1c protein levels were not
increased, whereas elevated acetylation levels were detected in
in vivo acetylation experiments under overnight fasting condi-
tions (Figs. 2 and 8). This may be partly due to the lack of a
complete understanding of in vivo regulations controlling
SREBP-1c levels, but overnight fasting could be amajor reason.
It was shown that GSK kinase phosphorylates SREBP-1c at
Ser-410 and destabilizes the protein and that insulin treat-
ment inhibits GSK activity, resulting in increased stability of
SREBP-1c (26). Therefore, overnight fasting may override the
acetylation effects on stability if elevated insulin levels are
required for the effect of SREBP-1c acetylation on its stability.
In the current studies, we show that SREBP-1c is an impor-
tant in vivo target of SIRT1. While this manuscript was under
revision, Na¨a¨r and colleagues (43) demonstrated that in re-
sponse to fasting cues, SIRT1 orthologs in metazoans play a
crucial role in inhibiting lipid/cholesterol synthesis by deacety-
lating and decreasing nuclear SREBP-1 and -2 levels. Therefore,
our studies, taken together with this study, consistently dem-
onstrate that increased activity and expression of SIRT1 during
fasting deacetylates and inhibits SREBP-1c activity, resulting in
down-regulation of lipogenic SREBP-1c gene expression and
subsequently decreased fat storage in the liver. Our studies fur-
ther suggest that abnormally elevated SREBP-1c acetylation
contributes to hepatic lipogenesis by increasing SREBP-1c ac-
tivity in obese mice.
SREBP-1c has been considered to be central to pathogenesis
of metabolic disorders, including fatty liver, and has received
much attention as a therapeutic target (15, 21–23, 43–45).
Small molecules to suppress SREBP-1c acetylation levels by
either inhibiting p300 or activating SIRT1 may be useful for
treatment of metabolic disorders, such as fatty liver disease,
obesity, and type II diabetes.
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